Nordic Glucoamylase Market Size & Outlook, 2026-2034
Nordic Glucoamylase Market Insights
- Based on Reed Intelligence findings, the Nordic Glucoamylase Market reached USD 17.64 Million in 2025 and is estimated to attain USD 32.29 Million by 2034.
- From 2026 to 2034, the Nordic market is expected to grow at a steady CAGR of 6.93%.
- Within the Type category, Microbial Glucoamylase dominated in 2025 in terms of market size contribution.
- Over the forecast period, Microbial Glucoamylase is forecasted to deliver the fastest growth, positioning it as the most lucrative Type segment.
Source: RI Analysis Company Publications, Primary Interviews.
Other Key Findings
- Nordic accounted for 1.68% of the global Glucoamylase Market size in 2025.
- By 2034, United States is expected to remain the top global market in terms of size.
- Within Europe, Germany is forecasted to dominate the regional Glucoamylase Market size by 2034.
- United Kingdom will be the fastest-growing market in Europe, projected to achieve USD 134.84 Million by 2034.
Report Summary
| Report Scope | Details |
|---|---|
| Base Year for Study | 2025 |
| Study Period | 2022-2034 |
| Historical Period | 2022-2024 |
| Forecast Period | 2026-2034 |
| Market Size In 2025 | USD 17.64 Million |
| Market Size In 2034 | USD 32.29 Million |
| Largest segment | Microbial Glucoamylase |
| Units | Revenue in USD Million |
| CAGR | 6.93% (2026-2034) |
| Segmnetation Covered | |
| Type |
|
| Application |
|
| End-Use Industry |
|
| Report Coverage | Revenue Forecast, Competitive Landscape, Growth Factors, Environment & Regulatory Landscape and Trends |
Nordic Glucoamylase Market Type 2026-2034 (USD Million)
| Type | 2022 | 2023 | 2024 | 2025 | 2026 | 2027 | 2028 | 2029 | 2030 | 2031 | 2032 | 2033 | 2034 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Microbial Glucoamylase | XX.x | XX.x | XX.x | 8.73 | XX.x | XX.x | XX.x | XX.x | XX.x | XX.x | XX.x | XX.x | XX.x |
| Plant-Based Glucoamylase | XX.x | XX.x | XX.x | XX.x | XX.x | XX.x | XX.x | XX.x | XX.x | XX.x | XX.x | XX.x | XX.x |
| Genetically Engineered Glucoamylase | XX.x | XX.x | XX.x | XX.x | XX.x | XX.x | XX.x | XX.x | XX.x | XX.x | XX.x | XX.x | XX.x |
| Total | XX.x | XX.x | XX.x | XX.x | XX.x | XX.x | XX.x | XX.x | XX.x | XX.x | XX.x | XX.x | XX.x |
Source: RI Analysis Company Publications, Primary Interviews.
Nordic Glucoamylase Market Application 2026-2034 (USD Million)
| Application | 2022 | 2023 | 2024 | 2025 | 2026 | 2027 | 2028 | 2029 | 2030 | 2031 | 2032 | 2033 | 2034 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Food & Beverage Processing | XX.x | XX.x | XX.x | 7.11 | XX.x | XX.x | XX.x | XX.x | XX.x | XX.x | XX.x | XX.x | XX.x |
| Bioethanol Production | XX.x | XX.x | XX.x | XX.x | XX.x | XX.x | XX.x | XX.x | XX.x | XX.x | XX.x | XX.x | XX.x |
| Animal Feed | XX.x | XX.x | XX.x | XX.x | XX.x | XX.x | XX.x | XX.x | XX.x | XX.x | XX.x | XX.x | XX.x |
| Pharmaceuticals | XX.x | XX.x | XX.x | XX.x | XX.x | XX.x | XX.x | XX.x | XX.x | XX.x | XX.x | XX.x | XX.x |
| Total | XX.x | XX.x | XX.x | XX.x | XX.x | XX.x | XX.x | XX.x | XX.x | XX.x | XX.x | XX.x | XX.x |
Source: RI Analysis Company Publications, Primary Interviews.
Nordic Glucoamylase Market End-Use Industry 2026-2034 (USD Million)
| End-Use Industry | 2022 | 2023 | 2024 | 2025 | 2026 | 2027 | 2028 | 2029 | 2030 | 2031 | 2032 | 2033 | 2034 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Food & Beverage Industry | XX.x | XX.x | XX.x | 7.07 | XX.x | XX.x | XX.x | XX.x | XX.x | XX.x | XX.x | XX.x | XX.x |
| Energy & Biofuel Industry | XX.x | XX.x | XX.x | XX.x | XX.x | XX.x | XX.x | XX.x | XX.x | XX.x | XX.x | XX.x | XX.x |
| Pharmaceutical & Biotechnology Industry | XX.x | XX.x | XX.x | XX.x | XX.x | XX.x | XX.x | XX.x | XX.x | XX.x | XX.x | XX.x | XX.x |
| Agriculture Industry | XX.x | XX.x | XX.x | XX.x | XX.x | XX.x | XX.x | XX.x | XX.x | XX.x | XX.x | XX.x | XX.x |
| Total | XX.x | XX.x | XX.x | XX.x | XX.x | XX.x | XX.x | XX.x | XX.x | XX.x | XX.x | XX.x | XX.x |
Source: RI Analysis Company Publications, Primary Interviews.
